Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Dormant

Current status date:

2022-06-01

Original market date: See footnote 1

2015-03-05

Product name:

PIPERACILLIN AND TAZOBACTAM FOR INJECTION

Description:

SINGLE USE VIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02401339

Product Monograph/Veterinary Labelling:

Date: 2022-05-27 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

HIKMA CANADA LIMITED
5995 Avebury Road, Suite 804
Mississauga
Ontario
Canada L5R 3P9

Class:

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

2

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

08:12.16.16 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

Active ingredient group (AIG) number:See footnote5

0225919006

List of active ingredient(s)
Active ingredient(s) Strength
PIPERACILLIN (PIPERACILLIN SODIUM) 4 G / VIAL
TAZOBACTAM (TAZOBACTAM SODIUM) 0.5 G / VIAL
Version 4.0.2
Date modified: